These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23978053)

  • 1. Clostridium difficile antibodies: a patent evaluation (WO2013028810).
    Lo Vecchio A; Della Ventura B; Nicastro E
    Expert Opin Ther Pat; 2013 Dec; 23(12):1635-40. PubMed ID: 23978053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
    Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
    PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
    Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
    Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
    Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
    Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.
    Yang Z; Shi L; Yu H; Zhang Y; Chen K; Saint Fleur A; Bai G; Feng H
    Pathog Dis; 2016 Oct; 74(7):. PubMed ID: 27502696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
    Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
    Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection.
    Gens KD; Elshaboury RH; Holt JS
    J Pharm Pract; 2013 Oct; 26(5):498-505. PubMed ID: 23966282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immune response as predictor of recurrence in Clostridium difficile infection.
    Bauer MP; Nibbering PH; Poxton IR; Kuijper EJ; van Dissel JT
    Clin Microbiol Infect; 2014 Dec; 20(12):1323-8. PubMed ID: 25041274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
    Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
    Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
    Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
    Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with monoclonal antibodies against Clostridium difficile toxins.
    Lowy I; Molrine DC; Leav BA; Blair BM; Baxter R; Gerding DN; Nichol G; Thomas WD; Leney M; Sloan S; Hay CA; Ambrosino DM
    N Engl J Med; 2010 Jan; 362(3):197-205. PubMed ID: 20089970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive immune response to Clostridium difficile infection: A perspective for prevention and therapy.
    Rees WD; Steiner TS
    Eur J Immunol; 2018 Mar; 48(3):398-406. PubMed ID: 29272036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clostridium difficile--beyond antibiotics.
    Kyne L
    N Engl J Med; 2010 Jan; 362(3):264-5. PubMed ID: 20089977
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
    Steele J; Mukherjee J; Parry N; Tzipori S
    J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
    Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
    Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with monoclonal antibodies against Clostridium difficile toxins.
    Safdar A
    N Engl J Med; 2010 Apr; 362(15):1444-5; author reply 1445-6. PubMed ID: 20397289
    [No Abstract]   [Full Text] [Related]  

  • 18. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options.
    Lo Vecchio A; Zacur GM
    Curr Opin Gastroenterol; 2012 Jan; 28(1):1-9. PubMed ID: 22134217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value.
    von Bechtolsheim F; Varga A; Szereday L; Polgar B; Balassa T; Kocsis B; Peterfi Z; Miko E
    J Microbiol Methods; 2019 Dec; 167():105777. PubMed ID: 31733265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.
    Hernandez LD; Racine F; Xiao L; DiNunzio E; Hairston N; Sheth PR; Murgolo NJ; Therien AG
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1052-60. PubMed ID: 25451052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.